Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy.
<h4>Background</h4>Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation...
Main Authors: | Shannon M Lenz, Jaymes H Collins, Nashone A Ray, Deanna A Hagge, Ramanuj Lahiri, Linda B Adams |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-09-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0008583 |
Similar Items
-
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy
by: Shannon M. Lenz, et al.
Published: (2020-09-01) -
Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States
by: Carlos Franco-Paredes, et al.
Published: (2022-11-01) -
A therapeutic study comparing the association of rifampin, ofloxacin and minocycline with the association of rifampin, clofazimine and dapsone in multibacillary leprosy patients
by: Ura Somei
Published: (2007-01-01) -
In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
by: Mariana Albano, et al.
Published: (2021-09-01) -
Successful desensitization to clarithromycin and moxifloxacin for the treatment of nontuberculous mycobacteria infection
by: Cheol Woo Kim, et al.
Published: (2020-08-01)